2019-07467. Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, PRAStaff@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at https://www.reginfo.gov/​public/​do/​PRAMain. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

    Table 1—List of Information Collections Approved by OMB

    Title of collectionOMB control No.Date approval expires
    Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution0910-004512/31/2021
    Biosimilar User Fee Program0910-071812/31/2021
    Surveys and Interviews with Investigational New Drug Sponsors to Assess Current Communication Practices with FDA Review Staff Under the Sixth Authorization of the Prescription Drug User Fee Act0910-086312/31/2021
    Disclosures of Descriptive Presentations in Professional Oncology Prescription Drug Promotion0910-086412/31/2021
    Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products0910-05721/31/2022
    General Licensing Provisions; Section 351(k) Biosimilar Applications0910-07191/31/2022
    Labeling of Certain Beers Subject to the Labeling Jurisdiction of the FDA0910-07281/31/2022
    Implementation of the Drug Supply Chain Security Act—Identification of Suspect Product and Notification0910-08061/31/2022
    Reclassification Petitions for Medical Devices0910-01382/28/2022
    Start Signature

    Dated: April 10, 2019.

    Lowell J. Schiller,

    Acting Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2019-07467 Filed 4-15-19; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
04/16/2019
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2019-07467
Pages:
15623-15623 (1 pages)
Docket Numbers:
Docket Nos. FDA-2011-N-0742, FDA-2018-N-1967, FDA-2018-N-2970, FDA-2017-N-1779, FDA-2008-N-0500, FDA-2012-N-0129, FDA-2009-D-0268, FDA-2014-D-0609, and FDA-2011-N-0776
PDF File:
2019-07467.pdf